Switzerland: Implementation Of Several Parts Of The Revised TPA And Pata As Well As Of The Therapeutic-Products-Ordinance-Package IV On 1 January 2019

On 21 September 2019, the Federal Council decided to implement several parts of the amendments adopted in the spring session 2016 regarding the legislation on therapeutic products and the law on patents as well as the corresponding ordinances on 1 January 2019. In order to complete the second stage of the ordinary revision of the legislation on therapeutic products, only the implementation of the provisions on integrity and transparency as well as the passing on of benefits is missing, which is expected to take place in the beginning of 2020.

Overview

On 18 March 2016, the Federal Assembly adopted the second stage of the ordinary revision of the Federal Act on Medicinal Products and Medical Devices (TPA). As a consequence, the corresponding ordinances had to be amended comprehensively (Therapeutic-Products-Ordinance-Package IV). The amendments concern ordinances both of the Federal Council and of the Institutional Board of the Swiss Agency for Therapeutic Products Swissmedic, namely

  • the (fully revised) Ordinance on Medicinal Products (VAM),
  • the Ordinance on Advertising of Medicinal Products (AWV),
  • the (new) Ordinance on the Supervisory Fee for the Benefit of the Swiss Agency for Therapeutic Products,
  • the Ordinance on Authorization of Medicinal Products (AMBV),
  • the Ordinance on the Simplified Authorization of Medicinal Products and the Authorization of Medicinal Products in the Notification Procedure (VAZV),
  • the (fully revised) Ordinance on Complementary and Herbal Medicinal Products (KPAV),
  • the (fully revised) Ordinance of the Swiss Agency for Therapeutic Products on its Fees, as well as
  • the (fully revised) Ordinance of the Swiss Agency for Therapeutic Products on its Personnel.

Based on the feedback from the consultation process regarding the Therapeutic-Products-Ordinance- Package IV, the draft ordinances were amended selectively.

With the decision of the Federal Council of 5 April 2017, several provisions of the revised TPA as well as the corresponding ordinances' provisions had already been implemented at the beginning of 2018, namely article 9 section 2 lit. f revTPA regarding the continuation of cantonal authorizations of medicines, as well as article 67a revTPA regarding the powers of the Federal Council to collect, harmonize, evaluate and publish data on the prescription, supply and use of medicines in pediatrics.

Furthermore, the revision entails amendments of the Federal Act on Patents for Inventions (PatA) and the Ordinance on Patents for Inventions (PatO) in order to promote medicines in pediatrics. The respective amendments will enter into force on 1 January 2019 as well.

Still pending is the implementation of the provisions on integrity and the obligation of transparency (namely articles 55 and 56 revTPA as well as the executive Ordinance on Integrity and Transparency in the Area of Therapeutic Products, VITH) as well as the provisions concerning the control of passing on benefits in the area of the mandatory health insurance (in particular article 56 section 3bis revTPA), which are expected to enter into force at the beginning of 2020 due to the necessary amendments on the ordinance level.

The Most Important Amendments Entering into Force on 1 January 2019

Facilitation of Market Access

In order to facilitate market access and to improve the availability of medicines for the population, article 14 section 1 lit. abis to aquater revTPA expand the possibility of the simplified authorization procedure to additional categories of medicines. The authorization of medicines with active ingredients that have has already been authorized in an EU- or EFTA-country ("well established use"), of medicines of long-standing use in another country ("traditional use") as well as of medicines with a pre-existing cantonal authorization will now follow the simplified procedure (cf. articles 17a et seq. revVAZV as well as section 1 of the annexes 4 to 5.3 to the revAMZV).

Prescription and Supply of Medicines

In the course of the revision of the rules on self-medication, the categories regarding dispensing will be restructured. While the fundamental division into medicines with or without prescription will be maintained, the former five categories will be reduced to four by dropping Category C (supply after consultation of a healthcare professional). Accordingly, in the future, articles 41 et seq. revVAM will provide for the following categorization:

  • Category A: Singular supply upon medical or veterinary prescription
  • Category B: Supply upon medical or veterinary prescription
  • Category D: Supply following professional consultation
  • Category E: Supply without professional consultation

The majority of medicines formerly belonging to Category C will be re-classified to Category D, with the exception of medicines which have to be assigned to Category B due to security reasons. Swissmedic is currently working on this, and the lists regarding the re-classification of all medicines of Category C are expected to be published in November 2018 as an advance information. The definite re-classification of the respective products will be made by way of ordinary administrative procedures following the implementation of the new legislation on medicines.

Furthermore, the revision aims at enhancing the exploitation of existing professional expertise when dispensing medicines by loosening the requirements for the supply of prescription medicines. Accordingly, pursuant to article 24 section 1 lit. a no. 1 revTPA, pharmacists may now generally dispense certain medicines of Category B without prescription. The respective medicines and indications as well as the documentation obligation are defined in article 45 et. seq. revVAM.

As a consequence the re-classification of many medicines of the former Category C to Category D, the dispensing competence of druggists will be expanded.

Additionally, article 52 revVAM defines the minimal requirements regarding the prescription of human medicines. The necessity of indicating the patient's address has been given up, and the requirements regarding the signing of the prescription have been modified in order to allow the electronic issuance without having to fulfill the strict conditions of a qualified electronic signature. However, article 51 section 1 revVAM only stipulates minimal requirements, and the cantons may demand further information such as the patient's contact details.

Security of Medicines

In order to improve the security of medicines, the legal bases of marketing authorization and market surveillance have been adapted to international developments. The key changes include the pediatric testing concept, the rules of good vigilance practice, the risk management plan as well as the expansion and specification of reporting obligations:

  • In the course of the authorization of medicines, pursuant to article 11 section 2 lit. a no. 6 in connection with article 54a revTPA, a pediatric testing concept (PTC) has to be submitted which includes the pediatric population into the development of new medicines. An exception from this obligation is possible, if the medicine is used to treat diseases which only occur in adults. Additionally, a PTC already assessed by a foreign authority may be taken into account. The respective provisions are to be found in articles 5 and 84 revVAM in particular.
  • In annex 3 of the revVAM, the recognized rules of the good vigilance practice are defined by referring to the guidelines of the International Conference on Harmonization (ICH), the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) regarding human medicines resp. the Veterinary International Conference on Harmonization (VICH) regarding veterinary medicines.
  • The risk management plan shall include risk evaluations and a pharmacovigilance-plan, which shall provide for the systematic assessment and evaluation of risks connected to the use of a medicine as well as for the respective prevention measures (cf. article 11 section 2 lit. a no. 5 revTPA and article 4 revVAM).
  • Finally, the reporting obligations regarding adverse effects and incidents in article 63 revVAM in connection with article 59 TPA has been expanded to professionals authorized to use or dispense medicines.

Improvement of Transparency

Whereas the provisions on transparency regarding discounts and remunerations will only be implemented later on, certain amendments aiming at improving transparency will enter into force on 1 January 2019. With regard to newly submitted applications for marketing authorizations, indication extensions or an expansion of a pre-existing marketing authorization, various details on the medicine and the holder/ applicant of the marketing authorization have to be published within 60 days. The same applies to (approved, and now also rejected) decisions on marketing authorization and withdrawals and to retractions of applications for authorization, indication extension or expansion of a pre-existing marketing authorization. Furthermore, the evaluation reports regarding human medicines with new active substances (Swiss Public Assessment Report, SwissPAR) on which the application is based as well as the reports on risk management plans have to be published. Additionally, for transparency reasons, the document protection period has to be published (cf. article 68 revVAM).

Furthermore, articles 77 et seq. revVAM as well as annex 5 of the revVAM stipulate that the holder of the marketing authorization of a human medicine is obliged to publish a summary of the relevant study results within three months after the marketing authorization has been granted, whereby a reference to internationally established public registers and databases of clinical studies shall be sufficient.

Strengthening of Research Incentives by Expanding Document Protection, and Extended Patent Protection for Pediatric Medicines

On 1 January 2019, the amendments regarding document protection stipulated in the medicinal product legislation as well as in the patent legislation will enter into force as well, aiming at creating new incentives regarding the development of medicines:

  • In the future, documentation regarding indications of known substances may be protected for a period of ten years (and not only of five years as before) upon request, if, compared to existing therapies, an important clinical benefit may be expected, and if the indication is supported by extensive clinical tests (cf. article 11b section 2 revTPA).
  • Regarding medicines intended especially or exclusively for pediatric use, Swissmedic allows for a document protection period of ten years, under the condition that no document protection has been granted for another medicine authorized by the agency with the same active substance for the same pediatric use (cf. article 11b section 3 revTPA).
  • Document protection regarding medicines for treating rare diseases (Orphan Drugs) may now be granted for a 15 year period upon request (cf. article 11b section 4 revTPA).
  • Anyone who contributes to the research and development of new medicines for children can now apply for a six-month extension of patent protection. The extension regarding pediatric medicines allowed under the revised PatA (cf. articles 140n to 140y revPatA) may consist of an extension of a pre-existing supplementary protection certificate or a new six-month pediatric protection certificate which is directly connected to the duration of the patent (cf. articles 127a to 127zbis revPatA). The requirements for the granting of the protection certificate are defined in the PatO.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions